


PALM INTRANET

Day : Sunday
Date: 8/24/2003
Time: 15:02:30

Docket
Reg. New
Reg. Amended
Spl. New
Spl. Amended
Rejected
Counted Not Mailed

Special New Cases

(WARNING: Data Security and Confidentiality Restriction Apply)

Name : **OWENS JR, HOWARD** Examiner Number : **74908**

Group Art Unit : **1623**

Special New Cases : 14

Oldest New S.N. : 09821103 Age: 04 Oldest Effective S.N. : 10231874 Age:04

Appln #	Filing Date	Status	Loc	Chg to Loc	Class	Subclass	Type	Title
<u>09/982315</u>	10/17/2001	30	16X1	16X1	514	456.000	DIV	COMPOSITIONS AND METHODS FOR CYSTIC FIBROSIS THERAPY
<u>10/040082</u>	10/26/2001	30	16L3	16C1	536	025.300	CON	PROCESS AND DEVICE FOR THE PARALLEL PREPARATION OF AT LEAST 4N OLIGONUCLEOTIDES
<u>10/007451</u>	11/06/2001	30	16X1	16X1	536	025.600	CON	CERTAIN DINUCLEOTIDES AND THEIR USE AS MODULATORS OF MUCOCILIARY CLEARANCE AND CILIARY BEAT FREQUENCY
<u>10/062665</u>	02/05/2002	30	16E1	16X1	556	489.000	DIV	SILICON-CONTAINING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME
<u>10/080074</u>	02/21/2002	30	16U2	16X1	536	022.100	REISS	PYRIMIDINE DERIVATIVES AND OLIGONUCLEOTIDES CONTAINING SAME
<u>10/104609</u>	03/22/2002	30	16E1	-	210	653.000	CON	CARBOHYDRATE PURIFICATION USING ULTRAFILTRATION, REVERSE OSMOSIS AND NANOFILTRATION
<u>10/190793</u>	07/09/2002	30	16C1	-	435	006.000	DIV	METHOD FOR QUANTIFYING CHOLESTEROL IN HIGH DENSITY LIPOPROTEIN
<u>10/202212</u>	07/22/2002	30	16C1	-	536	025.420	CON	NUCLEIC ACID-BONDABLE MAGNETIC CARRIER AND METHOD FOR ISOLATING NUCLEIC ACID USING THE SAME
<u>10/231874</u>	08/30/2002	30	16C1	-	536	025.400	CON	SYNTHESIS, DEPROTECTION, ANALYSIS & PURIFICATION OF RNA & RIBOZYMES
<u>10/253981</u>	09/24/2002	30	16C1	-	536	025.340	CON	PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS
								5'-SUBSTITUTED-RIBOFURANOSYL

10/263889	10/02/2002	30	16C1	-	514	115.000	CON	BENZIMIDAZOLES AS ANTIVIRAL AGENTS
10/266708	10/09/2002	30	16C1	-	514	310.000	CON	PHARMACEUTICAL COMPOSITION COMPRISING IFOSFAMIDE AND CARNITINE
10/294331	11/14/2002	30	16C3	-	514	456.000	CON	METHODS AND COMPOSITIONS FOR REGULATION OF 5-ALPHA REDUCTASE ACTIVITY
10/334824	12/31/2002	30	16C1	-	536	085.000	CON	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE AND PROCESS FOR PRODUCING SAME

[Docket](#)
[Reg. New](#)
[Reg. Amended](#)
[Spl. New](#)
[Spl. Amended](#)
[Rejected](#)
[Counted Not Mailed](#)

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
VIRUS	45552
VIRUSES	34157
VIRAL	38256
VIRALS	269
(3 AND (VIRAL OR VIRUS)).USPT.	96
((VIRUS OR VIRAL) AND L3).USPT.	96

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**DATE: Sunday, August 24, 2003 [Printable Copy](#) [Create Case](#)**Set Name Query**

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ

<u>L5</u>	(virus or viral) and l3	96	<u>L5</u>
<u>L4</u>	hcv and l3	5	<u>L4</u>
<u>L3</u>	hepatitis and (l2 or l1)	102	<u>L3</u>
<u>L2</u>	((514/50)!.CCLS.)	392	<u>L2</u>
<u>L1</u>	((514/49)!.CCLS.)	349	<u>L1</u>

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623HXO

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 AUG 22 Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
Right Truncation available
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 30 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31 AUG 15 PATDPAFULL: one FREE connect hour, per account, in
September 2003
NEWS 32 AUG 15 PCTGEN: one FREE connect hour, per account, in
September 2003
NEWS 33 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in
September 2003
NEWS 34 AUG 15 TEMA: one FREE connect hour, per account, in
September 2003
NEWS 35 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 36 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 37 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:55:34 ON 24 AUG 2003

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:55:46 ON 24 AUG 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2003 HIGHEST RN 571902-82-4
 DICTIONARY FILE UPDATES: 22 AUG 2003 HIGHEST RN 571902-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
 Uploading pyrknowles.str

L1 STRUCTURE UPLOADED

=> s l1 sss sam
 SAMPLE SEARCH INITIATED 17:56:23 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED	6 ITERATIONS	0 ANSWERS
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	6 TO	266

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 17:56:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 139 TO ITERATE

100.0% PROCESSED 139 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1


=> d scan

L3 4 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN Uridine, 5-methyl-2'-C-methyl- (9CI)

MF C11 H16 N2 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3 4 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN Uridine, 5-fluoro-2'-C-methyl- (8CI)

MF C10 H13 F N2 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 4 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Uridine, 2'-C-methyl- (8CI, 9CI)
MF C10 H14 N2 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 4 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2,4(1H,3H)-Pyrimidinedione, 1-(2-C-methyl-.beta.-D-arabinofuranosyl)-
(9CI)
MF C10 H14 N2 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
148.55	148.76

FILE 'CAPLUS' ENTERED AT 17:57:10 ON 24 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2003 VOL 139 ISS 9
FILE LAST UPDATED: 22 Aug 2003 (20030822/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:55:34 ON 24 AUG 2003)

FILE 'REGISTRY' ENTERED AT 17:55:46 ON 24 AUG 2003

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 4 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:57:10 ON 24 AUG 2003

=> s l3

L4 27 L3

=> s l4 and hepatitis

39204 HEPATITIS
L5 2 L4 AND HEPATITIS

=> s l4 and HCV

6784 HCV
17 HCVS
6788 HCV
(HCV OR HCVS)
L6 2 L4 AND HCV

=> s l4 and (virus or viral)

286545 VIRUS
61882 VIRUSES
296910 VIRUS
(VIRUS OR VIRUSES)
122754 VIRAL
7 VIRALS
122760 VIRAL
(VIRAL OR VIRALS)
L7 6 L4 AND (VIRUS OR VIRAL)

=> d 1-2 l5

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:555629 CAPLUS
DN 137:125359
TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
IN Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss, Malcolm; Olsen, David B.; Rutkowski, Carrie A.; Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha P.

PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SO PCT Int. Appl., 235 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057425	A2	20020725	WO 2002-US1531	20020118
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				
	UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002147160	A1	20021010	US 2002-52318	20020118
PRAI	US 2001-263313P	P	20010122		
	US 2001-282069P	P	20010406		
	US 2001-299320P	P	20010619		
	US 2001-344528P	P	20011025		
OS	MARPAT 137:125359				

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:868467 CAPLUS
 DN 136:6296
 TI Preparation of antiviral nucleosides and methods for treating
hepatitis C virus
 IN Sommadossi, Jean-Pierre; Lacolla, Paulo
 PA Novirio Pharmaceuticals Limited, Cayman I.; Universita degli Studi di
 Cagliari
 SO PCT Int. Appl., 296 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090121	A2	20011129	WO 2001-US16671	20010523
	WO 2001090121	A3	20020502		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001074906	A5	20011203	AU 2001-74906	20010523
	US 2003050229	A1	20030313	US 2001-864078	20010523
	EP 1292603	A2	20030319	EP 2001-941564	20010523
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011127	A	20030624	BR 2001-11127	20010523
	NO 2002005627	A	20030106	NO 2002-5627	20021122
PRAI	US 2000-206585P	P	20000523		
	WO 2001-US16671	W	20010523		
OS	MARPAT 136:6296				

=> d his

(FILE 'HOME' ENTERED AT 17:55:34 ON 24 AUG 2003)

FILE 'REGISTRY' ENTERED AT 17:55:46 ON 24 AUG 2003

L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 4 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:57:10 ON 24 AUG 2003

L4 27 S L3
L5 2 S L4 AND HEPATITIS
L6 2 S L4 AND HCV
L7 6 S L4 AND (VIRUS OR VIRAL)

=> d kwic ibib 1-2 16

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AB . . . prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and esp. as antiviral agents against HCV.

IT 20724-73-6 31448-54-1 119410-84-3 565450-97-7
565450-98-8 565450-99-9 565451-00-5 565451-01-6 565451-02-7
565451-03-8 565451-04-9 565451-05-0 565451-06-1 565451-07-2
565451-08-3 565451-09-4 565451-10-7 565451-11-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of sugar modified nucleosides as antiviral agents)

ACCESSION NUMBER: 2003:591195 CAPLUS

DOCUMENT NUMBER: 139:133789

TITLE: Preparation of sugar modified nucleosides as antiviral agents

INVENTOR(S): Hong, Zhi; An, Haoyun; Ding, Yili; Girardet, Jean-luc; Zhong, Weidong

PATENT ASSIGNEE(S): Ribapharm Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062255	A2	20030731	WO 2002-US31556	20021002
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-350296P P 20020117
US 2002-391800P P 20020626

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AB . . . are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. contg. such nucleoside

compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular **HCV** infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral. . . of the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the **HCV** NS5B polymerase assay exhibited IC's less than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of Hepatitis C Virus RNA in cultured hepatoma (HuH-7) cells contg. a sub-genomic **HCV** Replicon.

IT	86-01-1P	147-94-4P	606-58-6P	961-07-9P	2004-07-1P	2140-71-8P
	2140-79-6P	2504-55-4P	2564-35-4P	2946-39-6P	3258-05-7P	
	3868-32-4P	3868-33-5P	4016-63-1P	4209-30-7P	6736-58-9P	
	7013-16-3P	10058-66-9P	13191-15-6P	14675-48-0P	15676-18-3P	
	16220-07-8P	17210-68-3P	17434-81-0P	18417-89-5P	20724-73-6P	
	22423-10-5P	23197-98-0P	23567-96-6P	23567-97-7P	24121-00-4P	
	24909-13-5P	26383-05-1P	26889-39-4P	26889-42-9P	28072-46-0P	
	28072-49-3P	30948-06-2P	35874-49-8P	38819-10-2P	40725-89-1P	
	55968-37-1P	56039-11-3P	61210-21-7P	61468-90-4P	61556-44-3P	
	62160-23-0P	64183-27-3P	64526-34-7P	65114-35-4P	65444-12-4P	
	68345-70-0P	69199-40-2P	69383-05-7P	70932-91-1P	72490-81-4P	
	73449-07-7P	76617-73-7P	78153-66-9P	78842-13-4P	79816-01-6P	
	80791-87-3P	83379-31-1P	84017-61-8P	86392-75-8P	87202-41-3P	
	88970-14-3P	93366-96-2P	101212-50-4P	101515-08-6P	103122-85-6P	
	110880-39-2P	114262-49-6P	120244-38-4P	121196-59-6P		
	123402-24-4P	123402-25-5P	123402-27-7P	136208-63-4P	139209-26-0P	
	141232-24-8P	143028-98-2P	146897-64-5P	160527-01-5P	170468-34-5P	
	170468-36-7P	175787-23-2P	181356-39-8P	199859-58-0P	202186-97-8P	
	215942-59-9P	262417-55-0P	317820-43-2P	318247-10-8P	355805-46-8P	
	355805-55-9P	374750-27-3P	374750-28-4P	377048-28-7P	443642-28-2P	
	443642-29-3P	443642-34-0P	443642-38-4P	443642-41-9P	443642-42-0P	
	443642-43-1P	443642-44-2P	443642-45-3P	443642-46-4P	443642-47-5P	
	443642-48-6P	443642-49-7P	443642-53-3P	443642-56-6P	443642-57-7P	
	443642-60-2P	443642-63-5P	443642-66-8P	443642-67-9P	443642-74-8P	
	443642-80-6P	443642-83-9P	443642-86-2P	443642-87-3P	443642-88-4P	
	443642-89-5P	443642-95-3P	443642-96-4P	443642-97-5P	443642-98-6P	
	443643-26-3P	443643-28-5P	444018-74-0P	444018-76-2P	444018-79-5P	
	444018-81-9P	444018-85-3P	444018-88-6P	444018-90-0P	444018-92-2P	
	444018-96-6P	444018-99-9P	444019-02-7P	444019-03-8P	444019-05-0P	
	444019-09-4P	444019-12-9P	444019-15-2P	444019-17-4P	444019-19-6P	
	444019-21-0P	444019-23-2P	444019-25-4P	444019-27-6P	444019-29-8P	
	444019-30-1P	444019-39-0P	444019-40-3P	444019-41-4P	444019-42-5P	
	444019-43-6P	444019-44-7P	444019-45-8P	444019-46-9P	444019-47-0P	
	444019-48-1P	444019-49-2P	444019-50-5P	444019-51-6P	444019-52-7P	
	444019-53-8P	444019-54-9P	444019-55-0P	444019-56-1P	444019-57-2P	
	444019-58-3P	444019-59-4P	444019-60-7P	444019-61-8P	444019-62-9P	
	444019-63-0P	444019-64-1P	444019-65-2P	444019-66-3P	444019-67-4P	
	444019-68-5P	444019-69-6P	444019-70-9P	444019-71-0P	444019-72-1P	
	444019-73-2P	444019-74-3P	444019-75-4P	444019-76-5P	444019-77-6P	
	444019-78-7P	444019-79-8P	444019-80-1P	444019-81-2P	444019-82-3P	
	444019-83-4P	444019-84-5P	444019-87-8P	444019-99-2P	444020-04-6P	
	444020-09-1P	444020-20-6P	444020-25-1P	444020-48-8P	444020-62-6P	
	444020-64-8P	444020-66-0P	444020-69-3P	444020-70-6P	444020-71-7P	
	444020-72-8P	444020-73-9P	444020-74-0P	444020-75-1P	444020-76-2P	
	444020-77-3P	444020-78-4P	444020-79-5P	444020-80-8P	444020-81-9P	
	444020-82-0P	444020-83-1P	444020-84-2P	444020-85-3P	444020-86-4P	
	444020-87-5P	444020-88-6P	444020-89-7P	444020-90-0P		

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

ACCESSION NUMBER: 2002:555629 CAPLUS
 DOCUMENT NUMBER: 137:125359
 TITLE: Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
 INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss, Malcolm; Olsen, David B.; Rutkowski, Carrie A.; Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha P.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 235 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002147160	A1	20021010	US 2002-52318	20020118
PRIORITY APPLN. INFO.:			US 2001-263313P	P 20010122
			US 2001-282069P	P 20010406
			US 2001-299320P	P 20010619
			US 2001-344528P	P 20011025
OTHER SOURCE(S):		MARPAT 137:125359		

=> d his

(FILE 'HOME' ENTERED AT 17:55:34 ON 24 AUG 2003)

FILE 'REGISTRY' ENTERED AT 17:55:46 ON 24 AUG 2003

L1 STRUCTURE UPLOADED
 L2 0 S L1 SSS SAM
 L3 4 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:57:10 ON 24 AUG 2003

L4 27 S L3
 L5 2 S L4 AND HEPATITIS
 L6 2 S L4 AND HCV
 L7 6 S L4 AND (VIRUS OR VIRAL)

=> d kwic ibib 1-6 17

L7 ANSWER 1 OF 6 CAPLUS · COPYRIGHT 2003 ACS on STN
 IT Infection

(viral; prepn. of sugar modified nucleosides as antiviral agents)

IT 20724-73-6 31448-54-1 119410-84-3 565450-97-7
 565450-98-8 565450-99-9 565451-00-5 565451-01-6 565451-02-7
 565451-03-8 565451-04-9 565451-05-0 565451-06-1 565451-07-2
 565451-08-3 565451-09-4 565451-10-7 565451-11-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(prepn. of sugar modified nucleosides as antiviral agents)

ACCESSION NUMBER: 2003:591195 CAPLUS
DOCUMENT NUMBER: 139:133789
TITLE: Preparation of sugar modified nucleosides as antiviral
agents
INVENTOR(S): Hong, Zhi; An, Haoyun; Ding, Yili; Girardet, Jean-luc;
Zhong, Weidong
PATENT ASSIGNEE(S): Ribapharm Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062255	A2	20030731	WO 2002-US31556	20021002
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-350296P P 20020117
US 2002-391800P P 20020626

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA
viral polymerase
AB . . . CF3; R5 and R6 are independently H, hydroxymethyl, Me,
fluoromethyl; and certain derivs. thereof which are inhibitors of
RNA-dependent RNA viral polymerase. These compds. are
inhibitors of RNA-dependent RNA viral replication and are useful
for the treatment of RNA-dependent RNA viral infection. They
are particularly useful as inhibitors of hepatitis C virus (HCV)
NS5B polymerase, as inhibitors of HCV replication, and/or for the
treatment of hepatitis C infection. The invention also describes
pharmaceutical compns. contg. such nucleoside compds. alone or in
combination with other agents active against RNA-dependent RNA
viral infection, in particular HCV infection. Also disclosed are
methods of inhibiting RNA-dependent RNA polymerase, inhibiting
RNA-dependent RNA viral replication, and/or treating
RNA-dependent RNA viral infection with the nucleoside compds. of
the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-
ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of
RNA-dependent RNA viral polymerase. Representative compds.
tested in the HCV NS5B polymerase assay exhibited IC's less than 100
.mu.M. The compds. of the present invention were also evaluated for their
ability to affect the replication of Hepatitis C Virus RNA in
cultured hepatoma (HuH-7) cells contg. a sub-genomic HCV Replicon.
IT Antiviral agents
Cytotoxicity
Fever and Hyperthermia
Hepatitis C virus
Human
Infection

(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT RNA formation
(replication; prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT Infection
(viral; prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 9026-28-2, RNA-dependent RNA Polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Hepatitis C Virus NS5B; prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 9026-93-1, Adenosine deaminase
RL: CAT (Catalyst use); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 2140-72-9P, 2'-O-Methylcytidine 120401-36-7P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 86-01-1P 147-94-4P 606-58-6P 961-07-9P 2004-07-1P 2140-71-8P
2140-79-6P 2504-55-4P 2564-35-4P 2946-39-6P 3258-05-7P
3868-32-4P 3868-33-5P 4016-63-1P 4209-30-7P 6736-58-9P
7013-16-3P 10058-66-9P 13191-15-6P 14675-48-0P 15676-18-3P
16220-07-8P 17210-68-3P 17434-81-0P 18417-89-5P 20724-73-6P
22423-10-5P 23197-98-0P 23567-96-6P 23567-97-7P 24121-00-4P
24909-13-5P 26383-05-1P 26889-39-4P 26889-42-9P 28072-46-0P
28072-49-3P 30948-06-2P 35874-49-8P 38819-10-2P 40725-89-1P
55968-37-1P 56039-11-3P 61210-21-7P 61468-90-4P 61556-44-3P
62160-23-0P 64183-27-3P 64526-34-7P 65114-35-4P 65444-12-4P
68345-70-0P 69199-40-2P 69383-05-7P 70932-91-1P 72490-81-4P
73449-07-7P 76617-73-7P 78153-66-9P 78842-13-4P 79816-01-6P
80791-87-3P 83379-31-1P 84017-61-8P 86392-75-8P 87202-41-3P
88970-14-3P 93366-96-2P 101212-50-4P 101515-08-6P 103122-85-6P
110880-39-2P 114262-49-6P 120244-38-4P 121196-59-6P
123402-24-4P 123402-25-5P 123402-27-7P 136208-63-4P 139209-26-0P
141232-24-8P 143028-98-2P 146897-64-5P 160527-01-5P 170468-34-5P
170468-36-7P 175787-23-2P 181356-39-8P 199859-58-0P 202186-97-8P
215942-59-9P 262417-55-0P 317820-43-2P 318247-10-8P 355805-46-8P
355805-55-9P 374750-27-3P 374750-28-4P 377048-28-7P 443642-28-2P
443642-29-3P 443642-34-0P 443642-38-4P 443642-41-9P 443642-42-0P
443642-43-1P 443642-44-2P 443642-45-3P 443642-46-4P 443642-47-5P
443642-48-6P 443642-49-7P 443642-53-3P 443642-56-6P 443642-57-7P
443642-60-2P 443642-63-5P 443642-66-8P 443642-67-9P 443642-74-8P
443642-80-6P 443642-83-9P 443642-86-2P 443642-87-3P 443642-88-4P
443642-89-5P 443642-95-3P 443642-96-4P 443642-97-5P 443642-98-6P
443643-26-3P 443643-28-5P 444018-74-0P 444018-76-2P 444018-79-5P
444018-81-9P 444018-85-3P 444018-88-6P 444018-90-0P 444018-92-2P
444018-96-6P 444018-99-9P 444019-02-7P 444019-03-8P 444019-05-0P
444019-09-4P 444019-12-9P 444019-15-2P 444019-17-4P 444019-19-6P
444019-21-0P 444019-23-2P 444019-25-4P 444019-27-6P 444019-29-8P
444019-30-1P 444019-39-0P 444019-40-3P 444019-41-4P 444019-42-5P
444019-43-6P 444019-44-7P 444019-45-8P 444019-46-9P 444019-47-0P
444019-48-1P 444019-49-2P 444019-50-5P 444019-51-6P 444019-52-7P
444019-53-8P 444019-54-9P 444019-55-0P 444019-56-1P 444019-57-2P
444019-58-3P 444019-59-4P 444019-60-7P 444019-61-8P 444019-62-9P
444019-63-0P 444019-64-1P 444019-65-2P 444019-66-3P 444019-67-4P
444019-68-5P 444019-69-6P 444019-70-9P 444019-71-0P 444019-72-1P
444019-73-2P 444019-74-3P 444019-75-4P 444019-76-5P 444019-77-6P
444019-78-7P 444019-79-8P 444019-80-1P 444019-81-2P 444019-82-3P
444019-83-4P 444019-84-5P 444019-87-8P 444019-99-2P 444020-04-6P

444020-09-1P	444020-20-6P	444020-25-1P	444020-48-8P	444020-62-6P
444020-64-8P	444020-66-0P	444020-69-3P	444020-70-6P	444020-71-7P
444020-72-8P	444020-73-9P	444020-74-0P	444020-75-1P	444020-76-2P
444020-77-3P	444020-78-4P	444020-79-5P	444020-80-8P	444020-81-9P
444020-82-0P	444020-83-1P	444020-84-2P	444020-85-3P	444020-86-4P
444020-87-5P	444020-88-6P	444020-89-7P	444020-90-0P	

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT	444020-91-1P	444020-92-2P	444020-93-3P	444020-94-4P	444020-95-5P
	444020-96-6P	444020-97-7P	444020-98-8P	444020-99-9P	444021-00-5P
	444021-01-6P	444021-02-7P	444021-03-8P	444021-04-9P	444021-05-0P
	444021-06-1P	444021-07-2P	444021-08-3P	444021-09-4P	444021-10-7P
	444021-11-8P	444021-12-9P	444021-13-0P	444021-14-1P	444021-15-2P
	444021-16-3P	444021-17-4P	444021-18-5P	444021-19-6P	444021-20-9P
	444021-21-0P	444021-22-1P	444021-23-2P	444021-24-3P	444021-25-4P
	444021-28-7P	444021-29-8P	444021-30-1P	444021-31-2P	444021-32-3P
	444021-33-4P	444021-34-5P	444021-35-6P	444021-36-7P	444021-37-8P
	444021-38-9P	444021-39-0P	444021-40-3P	444021-41-4P	444021-42-5P
	444021-43-6P	444021-45-8P	444021-47-0P	444021-48-1P	444021-49-2P
	444021-52-7P	444021-55-0P	444021-58-3P	444021-60-7P	444021-62-9P
	444021-64-1P	444021-66-3P	444021-67-4P	444021-68-5P	444021-69-6P
	444021-70-9P	444021-71-0P	444021-72-1P	444021-73-2P	444021-74-3P
	444021-75-4P	444021-76-5P	444021-77-6P	444021-78-7P	444021-79-8P
	444021-80-1P	444021-81-2P	444021-82-3P	444021-83-4P	444021-84-5P
	444021-85-6P	444021-86-7P	444021-87-8P	444021-88-9P	444021-89-0P
	444021-90-3P	444021-91-4P	444021-92-5P	444021-93-6P	444021-94-7P
	444021-95-8P	444021-96-9P	444021-97-0P	444021-98-1P	444021-99-2P
	444022-00-8P	444022-01-9P	444022-02-0P	444022-03-1P	444022-04-2P
	444022-05-3P	444022-06-4P	444022-07-5P	444022-08-6P	444022-09-7P
	444022-10-0P	444022-11-1P	444022-12-2P	444022-13-3P	444022-14-4P
	444022-15-5P	444022-16-6P	444022-17-7P	444022-18-8P	444022-19-9P
	444022-20-2P	444022-21-3P	444022-22-4P	444022-23-5P	444022-24-6P
	444022-25-7P				

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT	90213-73-3P	90213-74-4P	115479-40-8P	115479-42-0P	161110-12-9P
	161169-94-4P	168427-35-8P	168777-53-5P	168777-55-7P	212061-24-0P
	212061-25-1P	312934-29-5P	312934-35-3P	312934-48-8P	317820-41-0P
	318246-85-4P	318246-92-3P	318247-02-8P	443642-30-6P	443642-31-7P
	443642-32-8P	443642-33-9P	443642-35-1P	443642-36-2P	443642-37-3P
	443642-39-5P	443642-40-8P	443642-50-0P	443642-51-1P	443642-52-2P
	443642-54-4P	443642-55-5P	443642-58-8P	443642-61-3P	443642-64-6P
	443642-68-0P	443642-69-1P	443642-70-4P	443642-71-5P	443642-72-6P
	443642-73-7P	443642-75-9P	443642-77-1P	443642-78-2P	443642-79-3P
	443642-84-0P	443642-85-1P	443642-90-8P	443642-91-9P	443642-92-0P
	443642-93-1P	443642-94-2P	444018-77-3P	444018-78-4P	444018-80-8P
	444018-82-0P	444018-83-1P	444018-84-2P	444018-86-4P	444018-87-5P
	444018-89-7P	444018-93-3P	444018-95-5P	444018-98-8P	444019-01-6P
	444019-04-9P	444019-06-1P	444019-08-3P	444019-10-7P	444019-13-0P
	444019-26-5P	444019-28-7P	444019-31-2P	444019-32-3P	444019-33-4P
	444019-34-5P	444019-35-6P	444019-36-7P	444019-37-8P	444019-38-9P
	444019-85-6P	444019-86-7P	444019-88-9P	444020-01-3P	

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 160526-82-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)
 (prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)
 IT 94-99-5 872-50-4, 1-Methyl-2-pyrrolidinone, uses
 RL: NUU (Other use, unclassified); USES (Uses)
 (prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)
 IT 60-24-2, 2-Mercaptoethanol 69-33-0, Tubercidin 124-07-2, Octanoic
 acid, reactions 524-38-9, N-Hydroxyphthalimide 937-14-4,
 3-Chloroperbenzoic acid 1618-36-6 2096-10-8, 2-Aminoadenosine
 2380-63-4, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine 3680-69-1 7057-33-2,
 3'-Deoxycytidine 15397-12-3 18422-43-0 19393-83-0 40635-67-4,
 .alpha.-Acetoxyisobutyryl bromide 56039-06-6 68703-51-5 70384-51-9
 79159-76-5 84955-31-7 85335-76-8 90358-16-0 102690-94-8
 102731-45-3 127047-59-0 129786-41-0 153121-88-1 168427-36-9
 171763-19-2 177414-97-0 213623-59-7 318246-79-6 443642-59-9
 443642-76-0 444018-75-1 444018-91-1 444018-94-4 444018-97-7
 444019-00-5 444019-07-2 444019-11-8 444019-14-1 444019-16-3
 444019-18-5 444019-20-9 444019-22-1 444019-24-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)
 IT 9012-90-2, DNA polymerase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha., .beta., and .gamma. human; prepn. of nucleoside derivs. as
 inhibitors of RNA-dependent human RNA **viral** polymerase)
 ACCESSION NUMBER: 2002:555629 CAPLUS
 DOCUMENT NUMBER: 137:125359
 TITLE: Preparation of nucleoside derivatives as inhibitors of
 RNA-dependent RNA **viral** polymerase
 INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn
 L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss,
 Malcolm; Olsen, David B.; Rutkowski, Carrie A.;
 Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen;
 Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.;
 Guinosso, Charles J.; Prhavic, Marija; Prakash, Thazha
 P.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 235 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,			
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,			
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,			
	UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002147160	A1	20021010	US 2002-52318	20020118
PRIORITY APPLN. INFO.:			US 2001-263313P	P 20010122
			US 2001-282069P	P 20010406
			US 2001-299320P	P 20010619
			US 2001-344528P	P 20011025
OTHER SOURCE(S):	MARPAT 137:125359			

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
 IT Antiviral agents
 Bovine diarrhea **virus**
 Cytotoxicity
 Drug bioavailability
 Flavivirus
 Pestivirus
 (nucleoside derivs. for treating flaviviruses and pestiviruses)
 IT 15397-12-3 16848-12-7 20724-73-6 **31448-54-1** 69123-98-4,
 FIAU **119410-84-3** 374750-30-8 374750-32-0
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
 activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nucleoside derivs. for treating flaviviruses and pestiviruses)
 ACCESSION NUMBER: 2001:886155 CAPLUS
 DOCUMENT NUMBER: 136:590
 TITLE: Methods and compositions using modified nucleosides
 for treating flaviviruses and pestiviruses
 INVENTOR(S): Sommadossi, Jean-Pierre; Lacolla, Paolo
 PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Universita
 Degli Studi Di Cagliari
 SOURCE: PCT Int. Appl., 302 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092282	A2	20011206	WO 2001-US16687	20010523
WO 2001092282	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1294735	A2	20030326	EP 2001-952131	20010523
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003060400	A1	20030327	US 2001-863816	20010523
NO 2002005600	A	20030117	NO 2002-5600	20021121
PRIORITY APPLN. INFO.:			US 2000-207674P	P 20000526
			US 2001-283276P	P 20010411
			WO 2001-US16687	W 20010523

OTHER SOURCE(S): MARPAT 136:590

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Preparation of antiviral nucleosides and methods for treating hepatitis C **virus**
 IT Hepatitis
 (C; prepn. of antiviral nucleosides and methods for treating hepatitis C **virus**)
 IT Antiviral agents
 Bone marrow
 Drug bioavailability
 Mitochondria
 Toxicity
 (prepn. of antiviral nucleosides and methods for treating hepatitis C **virus**)
 IT Nucleosides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antiviral nucleosides and methods for treating hepatitis C virus)

IT 36791-04-5, Ribavirin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of antiviral nucleosides and methods for treating hepatitis C virus)

IT 15397-12-3P 16848-12-7P 20724-73-6P 31448-54-1P
34441-68-4P 38946-83-7P 38946-84-8P 54401-19-3P 69123-98-4P
119410-84-3P 125911-76-4P 374750-27-3P 374750-28-4P
374750-29-5P 374750-30-8P 374750-31-9P 374750-32-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antiviral nucleosides and methods for treating hepatitis C virus)

ACCESSION NUMBER: 2001:868467 CAPLUS

DOCUMENT NUMBER: 136:6296

TITLE: Preparation of antiviral nucleosides and methods for treating hepatitis C virus

INVENTOR(S): Sommadossi, Jean-Pierre; Lacolla, Paulo

PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Universita degli Studi di Cagliari

SOURCE: PCT Int. Appl., 296 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090121	A2	20011129	WO 2001-US16671	20010523
WO 2001090121	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001074906	A5	20011203	AU 2001-74906	20010523
US 2003050229	A1	20030313	US 2001-864078	20010523
EP 1292603	A2	20030319	EP 2001-941564	20010523
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011127	A	20030624	BR 2001-11127	20010523
NO 2002005627	A	20030106	NO 2002-5627	20021122
PRIORITY APPLN. INFO.:			US 2000-206585P P	20000523
			WO 2001-US16671 W	20010523

OTHER SOURCE(S): MARPAT 136:6296

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AB . . . R4 = H) (V). I (R1 = NH2, R2 = R4 = H, R3 = Me) (VI) inhibited herpes simplex virus (HSV-1 and HSV-2) in vitro with a min. inhibitory concn. of 10 .mu.g/mL. Powder and capsule formulations were prepd. from. . .

IT 115494-63-8P 119410-83-2P 119410-84-3P 119410-85-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as virucide)

ACCESSION NUMBER: 1989:115271 CAPLUS
DOCUMENT NUMBER: 110:115271
TITLE: Preparation of 2'-deoxy-2'-(S)-alkylpyrimidine nucleosides as antiviral agents
INVENTOR(S): Ueda, Toru; Matsuda, Akira; Takenuki, Kenji; Machida, Haruhiko
PATENT ASSIGNEE(S): Yamasa Shoyu Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63215694	A2	19880908	JP 1987-49540	19870304
JP 06099467	B4	19941207		

PRIORITY APPLN. INFO.: JP 1987-49540 19870304
OTHER SOURCE(S): MARPAT 110:115271

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AB . . . an inhibiting concn.50 = 15 .mu.g/mL. None of the compds. showed antiviral activity against herpes simplex type 1 or 2 virus at 100 .mu.g/mL.

IT 114262-49-6P 116918-57-1P 116918-61-7P 116918-64-0P
116918-66-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

ACCESSION NUMBER: 1988:570788 CAPLUS
DOCUMENT NUMBER: 109:170788
TITLE: Nucleosides and nucleotides. LXXXI. Alkyl addition reaction of pyrimidine 2'-ketonucleosides: synthesis of 2'-branched-chain sugar pyrimidine nucleosides
AUTHOR(S): Matsuda, Akira; Itoh, Hiroko; Takenuki, Kenji; Sasaki, Takuma; Ueda, Tohru
CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, 060, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1988), 36(3), 945-53
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:170788

Uploading pyrknowles.str

L8 STRUCTURE UPLOADED

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
42.09	190.85

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.26	-3.26

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 18:19:37 ON 24 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2003 HIGHEST RN 571902-82-4
DICTIONARY FILE UPDATES: 22 AUG 2003 HIGHEST RN 571902-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNnote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s sss sam l8
SAMPLE SEARCH INITIATED 18:19:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s sss full l8
FULL SEARCH INITIATED 18:19:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L10 5 SEA SSS FUL L8

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.15	339.00

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.26

FILE 'CAPLUS' ENTERED AT 18:19:57 ON 24 AUG 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2003 VOL 139 ISS 9
 FILE LAST UPDATED: 22 Aug 2003 (20030822/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10

L11 12 L10

=> s l11 and hepatitis

39204 HEPATITIS

L12 2 L11 AND HEPATITIS

=> s l11 and (virus or viral)

286545 VIRUS

61882 VIRUSES

296910 VIRUS

(VIRUS OR VIRUSES)

122754 VIRAL

7 VIRALS

122760 VIRAL

(VIRAL OR VIRALS)

L13 5 L11 AND (VIRUS OR VIRAL)

=> s l11 and HCV

6784 HCV

17 HCVS

6788 HCV

(HCV OR HCVS)

L14 2 L11 AND HCV

=> d kwic ibib 1-2 l12

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AB viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of **hepatitis C virus (HCV)** NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of **hepatitis C** infection. The invention also describes pharmaceutical compns. contg. such nucleoside compds. alone or in combination with other agents active. . . . than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of **Hepatitis C Virus RNA** in cultured hepatoma

(HuH-7) cells contg. a sub-genomic HCV Replicon.

ST human cytotoxicity nucleoside prepn antiviral **hepatitis C**;
cytotoxicity nucleoside prepn antiviral **hepatitis C**; nucleoside
prepn inhibitor human RNA polymerase antiviral **hepatitis C**

IT Antiviral agents
Cytotoxicity
Fever and Hyperthermia
Hepatitis C virus
Human
Infection
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

IT 9026-28-2, RNA-dependent RNA Polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**Hepatitis C Virus NS5B**; prepn. of nucleoside derivs. as
inhibitors of RNA-dependent human RNA viral polymerase)

IT 86-01-1P 147-94-4P 606-58-6P 961-07-9P 2004-07-1P 2140-71-8P
2140-79-6P 2504-55-4P 2564-35-4P 2946-39-6P 3258-05-7P
3868-32-4P 3868-33-5P 4016-63-1P 4209-30-7P 6736-58-9P
7013-16-3P 10058-66-9P 13191-15-6P 14675-48-0P 15676-18-3P
16220-07-8P 17210-68-3P 17434-81-0P 18417-89-5P **20724-73-6P**
22423-10-5P 23197-98-0P 23567-96-6P 23567-97-7P 24121-00-4P
24909-13-5P 26383-05-1P 26889-39-4P 26889-42-9P 28072-46-0P
28072-49-3P 30948-06-2P 35874-49-8P 38819-10-2P 40725-89-1P
55968-37-1P 56039-11-3P 61210-21-7P 61468-90-4P 61556-44-3P
62160-23-0P 64183-27-3P 64526-34-7P 65114-35-4P 65444-12-4P
68345-70-0P 69199-40-2P 69383-05-7P 70932-91-1P 72490-81-4P
73449-07-7P 76617-73-7P 78153-66-9P 78842-13-4P 79816-01-6P
80791-87-3P 83379-31-1P 84017-61-8P 86392-75-8P 87202-41-3P
88970-14-3P 93366-96-2P 101212-50-4P 101515-08-6P 103122-85-6P
110880-39-2P 114262-49-6P 120244-38-4P 121196-59-6P 123402-24-4P
123402-25-5P 123402-27-7P 136208-63-4P 139209-26-0P 141232-24-8P
143028-98-2P 146897-64-5P 160527-01-5P 170468-34-5P 170468-36-7P
175787-23-2P 181356-39-8P 199859-58-0P 202186-97-8P 215942-59-9P
262417-55-0P 317820-43-2P 318247-10-8P 355805-46-8P 355805-55-9P
374750-27-3P 374750-28-4P 377048-28-7P 443642-28-2P 443642-29-3P
443642-34-0P 443642-38-4P 443642-41-9P 443642-42-0P 443642-43-1P
443642-44-2P 443642-45-3P 443642-46-4P 443642-47-5P 443642-48-6P
443642-49-7P 443642-53-3P 443642-56-6P 443642-57-7P 443642-60-2P
443642-63-5P 443642-66-8P 443642-67-9P 443642-74-8P 443642-80-6P
443642-83-9P 443642-86-2P 443642-87-3P 443642-88-4P 443642-89-5P
443642-95-3P 443642-96-4P 443642-97-5P 443642-98-6P 443643-26-3P
443643-28-5P 444018-74-0P 444018-76-2P 444018-79-5P 444018-81-9P
444018-85-3P 444018-88-6P 444018-90-0P 444018-92-2P 444018-96-6P
444018-99-9P 444019-02-7P 444019-03-8P 444019-05-0P 444019-09-4P
444019-12-9P 444019-15-2P 444019-17-4P 444019-19-6P 444019-21-0P
444019-23-2P 444019-25-4P 444019-27-6P 444019-29-8P 444019-30-1P
444019-39-0P 444019-40-3P 444019-41-4P 444019-42-5P 444019-43-6P
444019-44-7P 444019-45-8P 444019-46-9P 444019-47-0P 444019-48-1P
444019-49-2P 444019-50-5P 444019-51-6P 444019-52-7P 444019-53-8P
444019-54-9P 444019-55-0P 444019-56-1P 444019-57-2P 444019-58-3P
444019-59-4P 444019-60-7P 444019-61-8P 444019-62-9P 444019-63-0P
444019-64-1P 444019-65-2P 444019-66-3P 444019-67-4P 444019-68-5P
444019-69-6P 444019-70-9P 444019-71-0P 444019-72-1P 444019-73-2P
444019-74-3P 444019-75-4P 444019-76-5P 444019-77-6P 444019-78-7P
444019-79-8P 444019-80-1P 444019-81-2P 444019-82-3P 444019-83-4P
444019-84-5P 444019-87-8P 444019-99-2P 444020-04-6P 444020-09-1P
444020-20-6P 444020-25-1P 444020-48-8P 444020-62-6P 444020-64-8P
444020-66-0P 444020-69-3P 444020-70-6P 444020-71-7P 444020-72-8P
444020-73-9P 444020-74-0P 444020-75-1P 444020-76-2P 444020-77-3P
444020-78-4P 444020-79-5P 444020-80-8P 444020-81-9P 444020-82-0P
444020-83-1P 444020-84-2P 444020-85-3P 444020-86-4P 444020-87-5P
444020-88-6P 444020-89-7P 444020-90-0P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

ACCESSION NUMBER: 2002:555629 CAPLUS
DOCUMENT NUMBER: 137:125359
TITLE: Preparation of nucleoside derivatives as inhibitors of
RNA-dependent RNA viral polymerase
INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn
L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss,
Malcolm; Olsen, David B.; Rutkowski, Carrie A.;
Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen;
Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.;
Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha
P.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002147160	A1	20021010	US 2002-52318	20020118
PRIORITY APPLN. INFO.:			US 2001-263313P	P 20010122
			US 2001-282069P	P 20010406
			US 2001-299320P	P 20010619
			US 2001-344528P	P 20011025

OTHER SOURCE(S): MARPAT 137:125359

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
TI Preparation of antiviral nucleosides and methods for treating
hepatitis C virus
AB A method and compn. for treating a host infected with **hepatitis C** comprising administering an effective **hepatitis C** treatment amt. of a described 1'-, 2'- or 3'-modified nucleosides I, wherein : R1-R3 and R are independently H, . . .
IT **Hepatitis**
(C; prepn. of antiviral nucleosides and methods for treating **hepatitis C virus**)
IT Antiviral agents
Bone marrow
Drug bioavailability
Mitochondria
Toxicity
(prepn. of antiviral nucleosides and methods for treating **hepatitis C virus**)
IT Nucleosides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antiviral nucleosides and methods for treating
hepatitis C virus)

IT 36791-04-5, Ribavirin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (prepn. of antiviral nucleosides and methods for treating
hepatitis C virus)

IT 15397-12-3P 16848-12-7P 20724-73-6P 31448-54-1P
 34441-68-4P 38946-83-7P 38946-84-8P 54401-19-3P 69123-98-4P
 119410-84-3P 125911-76-4P 374750-27-3P 374750-28-4P 374750-29-5P
 374750-30-8P 374750-31-9P 374750-32-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of antiviral nucleosides and methods for treating
hepatitis C virus)

ACCESSION NUMBER: 2001:868467 CAPLUS
 DOCUMENT NUMBER: 136:6296
 TITLE: Preparation of antiviral nucleosides and methods for treating **hepatitis C virus**
 INVENTOR(S): Sommadossi, Jean-Pierre; Iacolla, Paulo
 PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Universita degli Studi di Cagliari
 SOURCE: PCT Int. Appl., 296 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090121	A2	20011129	WO 2001-US16671	20010523
WO 2001090121	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001074906	A5	20011203	AU 2001-74906	20010523
US 2003050229	A1	20030313	US 2001-864078	20010523
EP 1292603	A2	20030319	EP 2001-941564	20010523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011127	A	20030624	BR 2001-11127	20010523
NO 2002005627	A	20030106	NO 2002-5627	20021122
PRIORITY APPLN. INFO.:			US 2000-206585P	P 20000523
			WO 2001-US16671	W 20010523
OTHER SOURCE(S):			MARPAT 136:6296	

=> d his

(FILE 'HOME' ENTERED AT 17:55:34 ON 24 AUG 2003)

FILE 'REGISTRY' ENTERED AT 17:55:46 ON 24 AUG 2003

L1 STRUCTURE UPLOADED
 L2 0 S L1 SSS SAM
 L3 4 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:57:10 ON 24 AUG 2003

L4 27 S L3
L5 2 S L4 AND HEPATITIS
L6 2 S L4 AND HCV
L7 6 S L4 AND (VIRUS OR VIRAL)
L8 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 18:19:37 ON 24 AUG 2003

L9 0 S SSS SAM L8
L10 5 S SSS FULL L8

FILE 'CAPLUS' ENTERED AT 18:19:57 ON 24 AUG 2003

L11 12 S L10
L12 2 S L11 AND HEPATITIS
L13 5 S L11 AND (VIRUS OR VIRAL)
L14 2 S L11 AND HCV

=> d kwic ibib 1-2 l14

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AB . . . prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and esp. as antiviral agents against HCV.

IT 20724-73-6 31448-54-1 119410-84-3 565450-97-7 565450-98-8
565450-99-9 565451-00-5 565451-01-6 565451-02-7 565451-03-8
565451-04-9 565451-05-0 565451-06-1 565451-07-2
565451-08-3 565451-09-4 565451-10-7 565451-11-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of sugar modified nucleosides as antiviral agents)

ACCESSION NUMBER: 2003:591195 CAPLUS

DOCUMENT NUMBER: 139:133789

TITLE: Preparation of sugar modified nucleosides as antiviral agents

INVENTOR(S): Hong, Zhi; An, Haoyun; Ding, Yili; Girardet, Jean-luc; Zhong, Weidong

PATENT ASSIGNEE(S): Ribapharm Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062255	A2	20030731	WO 2002-US31556	20021002
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-350296P P 20020117
US 2002-391800P P 20020626

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AB . . . are useful for the treatment of RNA-dependent RNA viral

infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. contg. such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral. . . of the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the HCV NS5B polymerase assay exhibited IC's less than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of Hepatitis C Virus RNA in cultured hepatoma (HuH-7) cells contg. a sub-genomic HCV Replicon.

IT 86-01-1P 147-94-4P 606-58-6P 961-07-9P 2004-07-1P 2140-71-8P
 2140-79-6P 2504-55-4P 2564-35-4P 2946-39-6P 3258-05-7P
 3868-32-4P 3868-33-5P 4016-63-1P 4209-30-7P 6736-58-9P
 7013-16-3P 10058-66-9P 13191-15-6P 14675-48-0P 15676-18-3P
 16220-07-8P 17210-68-3P 17434-81-0P 18417-89-5P 20724-73-6P
 22423-10-5P 23197-98-0P 23567-96-6P 23567-97-7P 24121-00-4P
 24909-13-5P 26383-05-1P 26889-39-4P 26889-42-9P 28072-46-0P
 28072-49-3P 30948-06-2P 35874-49-8P 38819-10-2P 40725-89-1P
 55968-37-1P 56039-11-3P 61210-21-7P 61468-90-4P 61556-44-3P
 62160-23-0P 64183-27-3P 64526-34-7P 65114-35-4P 65444-12-4P
 68345-70-0P 69199-40-2P 69383-05-7P 70932-91-1P 72490-81-4P
 73449-07-7P 76617-73-7P 78153-66-9P 78842-13-4P 79816-01-6P
 80791-87-3P 83379-31-1P 84017-61-8P 86392-75-8P 87202-41-3P
 88970-14-3P 93366-96-2P 101212-50-4P 101515-08-6P 103122-85-6P
 110880-39-2P 114262-49-6P 120244-38-4P 121196-59-6P 123402-24-4P
 123402-25-5P 123402-27-7P 136208-63-4P 139209-26-0P 141232-24-8P
 143028-98-2P 146897-64-5P 160527-01-5P 170468-34-5P 170468-36-7P
 175787-23-2P 181356-39-8P 199859-58-0P 202186-97-8P 215942-59-9P
 262417-55-0P 317820-43-2P 318247-10-8P 355805-46-8P 355805-55-9P
 374750-27-3P 374750-28-4P 377048-28-7P 443642-28-2P 443642-29-3P
 443642-34-0P 443642-38-4P 443642-41-9P 443642-42-0P 443642-43-1P
 443642-44-2P 443642-45-3P 443642-46-4P 443642-47-5P 443642-48-6P
 443642-49-7P 443642-53-3P 443642-56-6P 443642-57-7P 443642-60-2P
 443642-63-5P 443642-66-8P 443642-67-9P 443642-74-8P 443642-80-6P
 443642-83-9P 443642-86-2P 443642-87-3P 443642-88-4P 443642-89-5P
 443642-95-3P 443642-96-4P 443642-97-5P 443642-98-6P 443643-26-3P
 443643-28-5P 444018-74-0P 444018-76-2P 444018-79-5P 444018-81-9P
 444018-85-3P 444018-88-6P 444018-90-0P 444018-92-2P 444018-96-6P
 444018-99-9P 444019-02-7P 444019-03-8P 444019-05-0P 444019-09-4P
 444019-12-9P 444019-15-2P 444019-17-4P 444019-19-6P 444019-21-0P
 444019-23-2P 444019-25-4P 444019-27-6P 444019-29-8P 444019-30-1P
 444019-39-0P 444019-40-3P 444019-41-4P 444019-42-5P 444019-43-6P
 444019-44-7P 444019-45-8P 444019-46-9P 444019-47-0P 444019-48-1P
 444019-49-2P 444019-50-5P 444019-51-6P 444019-52-7P 444019-53-8P
 444019-54-9P 444019-55-0P 444019-56-1P 444019-57-2P 444019-58-3P
 444019-59-4P 444019-60-7P 444019-61-8P 444019-62-9P 444019-63-0P
 444019-64-1P 444019-65-2P 444019-66-3P 444019-67-4P 444019-68-5P
 444019-69-6P 444019-70-9P 444019-71-0P 444019-72-1P 444019-73-2P
 444019-74-3P 444019-75-4P 444019-76-5P 444019-77-6P 444019-78-7P
 444019-79-8P 444019-80-1P 444019-81-2P 444019-82-3P 444019-83-4P
 444019-84-5P 444019-87-8P 444019-99-2P 444020-04-6P 444020-09-1P
 444020-20-6P 444020-25-1P 444020-48-8P 444020-62-6P 444020-64-8P
 444020-66-0P 444020-69-3P 444020-70-6P 444020-71-7P 444020-72-8P
 444020-73-9P 444020-74-0P 444020-75-1P 444020-76-2P 444020-77-3P
 444020-78-4P 444020-79-5P 444020-80-8P 444020-81-9P 444020-82-0P
 444020-83-1P 444020-84-2P 444020-85-3P 444020-86-4P 444020-87-5P
 444020-88-6P 444020-89-7P 444020-90-0P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
 viral polymerase)

ACCESSION NUMBER: 2002:555629 CAPLUS
 DOCUMENT NUMBER: 137:125359
 TITLE: Preparation of nucleoside derivatives as inhibitors of
 RNA-dependent RNA viral polymerase
 INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn
 L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss,
 Malcolm; Olsen, David B.; Rutkowski, Carrie A.;
 Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen;
 Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.;
 Guinasso, Charles J.; Prhavic, Marija; Prakash, Thazha
 P.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 235 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002147160	A1	20021010	US 2002-52318	20020118
PRIORITY APPLN. INFO.:			US 2001-263313P	P 20010122
			US 2001-282069P	P 20010406
			US 2001-299320P	P 20010619
			US 2001-344528P	P 20011025
OTHER SOURCE(S):		MARPAT 137:125359		

=> remove dup

DUP IS NOT VALID HERE

The DELETE command is used to remove various items stored by the
 system.

To delete a saved query, saved answer set, saved L-number list, SDI
 request, batch request, mailing list, or user-defined cluster, format,
 or search field, enter the name. The name may include ? for left,
 right, or simultaneous left and right truncation.

Examples:

DELETE BIO?/Q	- delete query names starting with BIO
DELETE ?DRUG/A	- delete answer set names ending with DRUG
DELETE ?ELEC?/L	- delete L-number lists containing ELEC
DELETE ANTICOAG/S	- delete SDI request
DELETE ENZYME/B	- delete batch request
DELETE .MYCLUSTER	- delete user-defined cluster
DELETE .MYFORMAT	- delete user-defined display format
DELETE .MYFIELD	- delete user-defined search field
DELETE NAMELIST MYLIST	- delete mailing list

To delete an ordered document or an offline print, enter its number.

Examples:

```
DELETE P123001C      - delete print request
DELETE D134002C      - delete document order request
```

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

```
DELETE L21           - delete a single L-number
DELETE L3-L6         - delete a range of L-numbers
DELETE LAST 4        - delete the last 4 L-numbers
DELETE L33-          - delete L33 and any higher L-number
DELETE -L55          - delete L55 and any lower L-number
DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                      renumber remaining L-numbers
DELETE RENUMBER       - renumber L-numbers after deletion of
                      intermediate L-numbers
```

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

```
DELETE SAVED/Q - delete all saved queries
DELETE SAVED/A - delete all saved answer sets
DELETE SAVED/L - delete all saved L-number lists
DELETE SAVED   - delete all saved queries, answer sets,
                  and L-number lists
DELETE SAVED/S - delete all SDI requests
DELETE SAVED/B - delete all batch requests
DELETE CLUSTER - delete all user-defined clusters
DELETE FORMAT  - delete all user-defined display formats
DELETE FIELD   - delete all user-defined search fields
DELETE SELECT  - delete all E-numbers
DELETE HISTORY - delete all L-numbers and restart the
                  session at L1
```

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

=> d his

(FILE 'HOME' ENTERED AT 17:55:34 ON 24 AUG 2003)

FILE 'REGISTRY' ENTERED AT 17:55:46 ON 24 AUG 2003

```
L1      STRUCTURE UPLOADED
L2      0 S L1 SSS SAM
L3      4 S L1 SSS FULL
```

FILE 'CAPLUS' ENTERED AT 17:57:10 ON 24 AUG 2003

```
L4      27 S L3
L5      2 S L4 AND HEPATITIS
L6      2 S L4 AND HCV
L7      6 S L4 AND (VIRUS OR VIRAL)
```

L8 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 18:19:37 ON 24 AUG 2003

L9	0	S	SSS	SAM	L8
L10	5	S	SSS	FULL	L8

FILE 'CAPLUS' ENTERED AT 18:19:57 ON 24 AUG 2003

```

L11      12 S L10
L12      2 S L11 AND HEPATITIS
L13      5 S L11 AND (VIRUS OR VIRAL)
L14      2 S L11 AND HCV

```

```
=> delete l13
DELETE L13? (Y)/N:n
```

```
=> dup l13
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
PROCESSING COMPLETED FOR L13
L15          5 DUP REMOVE L13 (0 DUPLICATES REMOVED)
```

=> d kwic ibib 115 1-5

L15 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

IT Infection
(viral; prepn. of sugar modified nucleosides as antiviral agents)

IT	20724-73-6	31448-54-1	119410-84-3	565450-97-7	565450-98-8
	565450-99-9	565451-00-5	565451-01-6	565451-02-7	565451-03-8
	565451-04-9	565451-05-0	565451-06-1	565451-07-2	
	565451-08-3	565451-09-4	565451-10-7	565451-11-8	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of sugar modified nucleosides as antiviral agents)

ACCESSION NUMBER: 2003:591195 CAPLUS

DOCUMENT NUMBER: 139:133789

TITLE: Preparation of sugar modified nucleosides as antiviral agents

INVENTOR(S) : Hong, Zhi; An, Haoyun; Ding, Yili; Girardet, Jean-luc;
Zhong, Weidong

PATENT ASSIGNEE(S) : Ribapharm Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062255	A2	20030731	WO 2002-US31556	20021002

W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2002-350296P	P	20020117
	US 2002-391800P	P	20020626

L15 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

AB . . . CF3; R5 and R6 are independently H, hydroxymethyl, Me, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. contg. such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-1-(2-C-methyl-.beta.-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepd. as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the HCV NS5B polymerase assay exhibited IC's less than 100 .mu.M. The compds. of the present invention were also evaluated for their ability to affect the replication of Hepatitis C Virus RNA in cultured hepatoma (HuH-7) cells contg. a sub-genomic HCV Replicon.

IT Antiviral agents
Cytotoxicity
Fever and Hyperthermia
Hepatitis C virus
Human
Infection
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT RNA formation
(replication; prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT Infection
(viral; prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 9026-28-2, RNA-dependent RNA Polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (Hepatitis C Virus NS5B; prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 9026-93-1, Adenosine deaminase
RL: CAT (Catalyst use); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 2140-72-9P, 2'-O-Methylcytidine 120401-36-7P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

IT 86-01-1P 147-94-4P 606-58-6P 961-07-9P 2004-07-1P 2140-71-8P
2140-79-6P 2504-55-4P 2564-35-4P 2946-39-6P 3258-05-7P
3868-32-4P 3868-33-5P 4016-63-1P 4209-30-7P 6736-58-9P
7013-16-3P 10058-66-9P 13191-15-6P 14675-48-0P 15676-18-3P
16220-07-8P 17210-68-3P 17434-81-0P 18417-89-5P 20724-73-6P
22423-10-5P 23197-98-0P 23567-96-6P 23567-97-7P 24121-00-4P
24909-13-5P 26383-05-1P 26889-39-4P 26889-42-9P 28072-46-0P
28072-49-3P 30948-06-2P 35874-49-8P 38819-10-2P 40725-89-1P
55968-37-1P 56039-11-3P 61210-21-7P 61468-90-4P 61556-44-3P
62160-23-0P 64183-27-3P 64526-34-7P 65114-35-4P 65444-12-4P
68345-70-0P 69199-40-2P 69383-05-7P 70932-91-1P 72490-81-4P

73449-07-7P	76617-73-7P	78153-66-9P	78842-13-4P	79816-01-6P
80791-87-3P	83379-31-1P	84017-61-8P	86392-75-8P	87202-41-3P
88970-14-3P	93366-96-2P	101212-50-4P	101515-08-6P	103122-85-6P
110880-39-2P	114262-49-6P	120244-38-4P	121196-59-6P	123402-24-4P
123402-25-5P	123402-27-7P	136208-63-4P	139209-26-0P	141232-24-8P
143028-98-2P	146897-64-5P	160527-01-5P	170468-34-5P	170468-36-7P
175787-23-2P	181356-39-8P	199859-58-0P	202186-97-8P	215942-59-9P
262417-55-0P	317820-43-2P	318247-10-8P	355805-46-8P	355805-55-9P
374750-27-3P	374750-28-4P	377048-28-7P	443642-28-2P	443642-29-3P
443642-34-0P	443642-38-4P	443642-41-9P	443642-42-0P	443642-43-1P
443642-44-2P	443642-45-3P	443642-46-4P	443642-47-5P	443642-48-6P
443642-49-7P	443642-53-3P	443642-56-6P	443642-57-7P	443642-60-2P
443642-63-5P	443642-66-8P	443642-67-9P	443642-74-8P	443642-80-6P
443642-83-9P	443642-86-2P	443642-87-3P	443642-88-4P	443642-89-5P
443642-95-3P	443642-96-4P	443642-97-5P	443642-98-6P	443643-26-3P
443643-28-5P	444018-74-0P	444018-76-2P	444018-79-5P	444018-81-9P
444018-85-3P	444018-88-6P	444018-90-0P	444018-92-2P	444018-96-6P
444018-99-9P	444019-02-7P	444019-03-8P	444019-05-0P	444019-09-4P
444019-12-9P	444019-15-2P	444019-17-4P	444019-19-6P	444019-21-0P
444019-23-2P	444019-25-4P	444019-27-6P	444019-29-8P	444019-30-1P
444019-39-0P	444019-40-3P	444019-41-4P	444019-42-5P	444019-43-6P
444019-44-7P	444019-45-8P	444019-46-9P	444019-47-0P	444019-48-1P
444019-49-2P	444019-50-5P	444019-51-6P	444019-52-7P	444019-53-8P
444019-54-9P	444019-55-0P	444019-56-1P	444019-57-2P	444019-58-3P
444019-59-4P	444019-60-7P	444019-61-8P	444019-62-9P	444019-63-0P
444019-64-1P	444019-65-2P	444019-66-3P	444019-67-4P	444019-68-5P
444019-69-6P	444019-70-9P	444019-71-0P	444019-72-1P	444019-73-2P
444019-74-3P	444019-75-4P	444019-76-5P	444019-77-6P	444019-78-7P
444019-79-8P	444019-80-1P	444019-81-2P	444019-82-3P	444019-83-4P
444019-84-5P	444019-87-8P	444019-99-2P	444020-04-6P	444020-09-1P
444020-20-6P	444020-25-1P	444020-48-8P	444020-62-6P	444020-64-8P
444020-66-0P	444020-69-3P	444020-70-6P	444020-71-7P	444020-72-8P
444020-73-9P	444020-74-0P	444020-75-1P	444020-76-2P	444020-77-3P
444020-78-4P	444020-79-5P	444020-80-8P	444020-81-9P	444020-82-0P
444020-83-1P	444020-84-2P	444020-85-3P	444020-86-4P	444020-87-5P
444020-88-6P	444020-89-7P	444020-90-0P		

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
 viral polymerase)

IT	444020-91-1P	444020-92-2P	444020-93-3P	444020-94-4P	444020-95-5P
	444020-96-6P	444020-97-7P	444020-98-8P	444020-99-9P	444021-00-5P
	444021-01-6P	444021-02-7P	444021-03-8P	444021-04-9P	444021-05-0P
	444021-06-1P	444021-07-2P	444021-08-3P	444021-09-4P	444021-10-7P
	444021-11-8P	444021-12-9P	444021-13-0P	444021-14-1P	444021-15-2P
	444021-16-3P	444021-17-4P	444021-18-5P	444021-19-6P	444021-20-9P
	444021-21-0P	444021-22-1P	444021-23-2P	444021-24-3P	444021-25-4P
	444021-28-7P	444021-29-8P	444021-30-1P	444021-31-2P	444021-32-3P
	444021-33-4P	444021-34-5P	444021-35-6P	444021-36-7P	444021-37-8P
	444021-38-9P	444021-39-0P	444021-40-3P	444021-41-4P	444021-42-5P
	444021-43-6P	444021-45-8P	444021-47-0P	444021-48-1P	444021-49-2P
	444021-52-7P	444021-55-0P	444021-58-3P	444021-60-7P	444021-62-9P
	444021-64-1P	444021-66-3P	444021-67-4P	444021-68-5P	444021-69-6P
	444021-70-9P	444021-71-0P	444021-72-1P	444021-73-2P	444021-74-3P
	444021-75-4P	444021-76-5P	444021-77-6P	444021-78-7P	444021-79-8P
	444021-80-1P	444021-81-2P	444021-82-3P	444021-83-4P	444021-84-5P
	444021-85-6P	444021-86-7P	444021-87-8P	444021-88-9P	444021-89-0P
	444021-90-3P	444021-91-4P	444021-92-5P	444021-93-6P	444021-94-7P
	444021-95-8P	444021-96-9P	444021-97-0P	444021-98-1P	444021-99-2P
	444022-00-8P	444022-01-9P	444022-02-0P	444022-03-1P	444022-04-2P
	444022-05-3P	444022-06-4P	444022-07-5P	444022-08-6P	444022-09-7P
	444022-10-0P	444022-11-1P	444022-12-2P	444022-13-3P	444022-14-4P
	444022-15-5P	444022-16-6P	444022-17-7P	444022-18-8P	444022-19-9P

444022-20-2P 444022-21-3P 444022-22-4P 444022-23-5P 444022-24-6P
444022-25-7P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

IT 90213-73-3P 90213-74-4P 115479-40-8P 115479-42-0P 161110-12-9P
161169-94-4P 168427-35-8P 168777-53-5P 168777-55-7P 212061-24-0P
212061-25-1P 312934-29-5P 312934-35-3P 312934-48-8P 317820-41-0P
318246-85-4P 318246-92-3P 318247-02-8P 443642-30-6P 443642-31-7P
443642-32-8P 443642-33-9P 443642-35-1P 443642-36-2P 443642-37-3P
443642-39-5P 443642-40-8P 443642-50-0P 443642-51-1P 443642-52-2P
443642-54-4P 443642-55-5P 443642-58-8P 443642-61-3P 443642-64-6P
443642-68-0P 443642-69-1P 443642-70-4P 443642-71-5P 443642-72-6P
443642-73-7P 443642-75-9P 443642-77-1P 443642-78-2P 443642-79-3P
443642-84-0P 443642-85-1P 443642-90-8P 443642-91-9P 443642-92-0P
443642-93-1P 443642-94-2P 444018-77-3P 444018-78-4P 444018-80-8P
444018-82-0P 444018-83-1P 444018-84-2P 444018-86-4P 444018-87-5P
444018-89-7P 444018-93-3P 444018-95-5P 444018-98-8P 444019-01-6P
444019-04-9P 444019-06-1P 444019-08-3P 444019-10-7P 444019-13-0P
444019-26-5P 444019-28-7P 444019-31-2P 444019-32-3P 444019-33-4P
444019-34-5P 444019-35-6P 444019-36-7P 444019-37-8P 444019-38-9P
444019-85-6P 444019-86-7P 444019-88-9P 444020-01-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic
preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

IT 160526-82-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

IT 94-99-5 872-50-4, 1-Methyl-2-pyrrolidinone, uses
RL: NUU (Other use, unclassified); USES (Uses)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

IT 60-24-2, 2-Mercaptoethanol 69-33-0, Tubercidin 124-07-2, Octanoic
acid, reactions 524-38-9, N-Hydroxyphthalimide 937-14-4,
3-Chloroperbenzoic acid 1618-36-6 2096-10-8, 2-Aminoadenosine
2380-63-4, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine 3680-69-1 7057-33-2,
3'-Deoxycytidine 15397-12-3 18422-43-0 19393-83-0 40635-67-4,
.alpha.-Acetoxyisobutyryl bromide 56039-06-6 68703-51-5 70384-51-9
79159-76-5 84955-31-7 85335-76-8 90358-16-0 102690-94-8
102731-45-3 127047-59-0 129786-41-0 153121-88-1 168427-36-9
171763-19-2 177414-97-0 213623-59-7 318246-79-6 443642-59-9
443642-76-0 444018-75-1 444018-91-1 444018-94-4 444018-97-7
444019-00-5 444019-07-2 444019-11-8 444019-14-1 444019-16-3
444019-18-5 444019-20-9 444019-22-1 444019-24-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of nucleoside derivs. as inhibitors of RNA-dependent human RNA
viral polymerase)

IT 9012-90-2, DNA polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., .beta., and .gamma. human; prepn. of nucleoside derivs. as
inhibitors of RNA-dependent human RNA viral polymerase)

ACCESSION NUMBER: 2002:555629 CAPLUS

DOCUMENT NUMBER: 137:125359

TITLE: Preparation of nucleoside derivatives as inhibitors of
RNA-dependent RNA viral polymerase

INVENTOR(S): Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn
L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss,
Malcolm; Olsen, David B.; Rutkowski, Carrie A.;
Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen;

Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.;
Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha
P.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057425	A2	20020725	WO 2002-US1531	20020118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002147160	A1	20021010	US 2002-52318	20020118
PRIORITY APPLN. INFO.:			US 2001-263313P	P 20010122
			US 2001-282069P	P 20010406
			US 2001-299320P	P 20010619
			US 2001-344528P	P 20011025

OTHER SOURCE(S): MARPAT 137:125359

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
IT Antiviral agents
Bovine diarrhea virus
Cytotoxicity
Drug bioavailability
Flavivirus
Pestivirus
(nucleoside derivs. for treating flaviviruses and pestiviruses)
IT 15397-12-3 16848-12-7 20724-73-6 31448-54-1 69123-98-4,
FIAU 119410-84-3 374750-30-8 374750-32-0
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside derivs. for treating flaviviruses and pestiviruses)
ACCESSION NUMBER: 2001:886155 CAPLUS
DOCUMENT NUMBER: 136:590
TITLE: Methods and compositions using modified nucleosides for treating flaviviruses and pestiviruses
INVENTOR(S): Sommadossi, Jean-Pierre; Lacolla, Paolo
PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Universita Degli Studi Di Cagliari
SOURCE: PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092282	A2	20011206	WO 2001-US16687	20010523
WO 2001092282	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1294735 A2 20030326 EP 2001-952131 20010523
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2003060400 A1 20030327 US 2001-863816 20010523
 NO 2002005600 A 20030117 NO 2002-5600 20021121
 PRIORITY APPLN. INFO.: US 2000-207674P P 20000526
 US 2001-283276P P 20010411
 WO 2001-US16687 W 20010523
 OTHER SOURCE(S): MARPAT 136:590

L15 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 TI Preparation of antiviral nucleosides and methods for treating hepatitis C
 virus
 IT Hepatitis
 (C; prepn. of antiviral nucleosides and methods for treating hepatitis
 C virus)
 IT Antiviral agents
 Bone marrow
 Drug bioavailability
 Mitochondria
 Toxicity
 (prepn. of antiviral nucleosides and methods for treating hepatitis C
 virus)
 IT Nucleosides, preparation
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); IMF (Industrial manufacture); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of antiviral nucleosides and methods for treating hepatitis C
 virus)
 IT 36791-04-5, Ribavirin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (prepn. of antiviral nucleosides and methods for treating hepatitis C
 virus)
 IT 15397-12-3P 16848-12-7P 20724-73-6P 31448-54-1P
 34441-68-4P 38946-83-7P 38946-84-8P 54401-19-3P 69123-98-4P
 119410-84-3P 125911-76-4P 374750-27-3P 374750-28-4P 374750-29-5P
 374750-30-8P 374750-31-9P 374750-32-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); IMF (Industrial manufacture); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of antiviral nucleosides and methods for treating hepatitis C
 virus)
 ACCESSION NUMBER: 2001:868467 CAPLUS
 DOCUMENT NUMBER: 136:6296
 TITLE: Preparation of antiviral nucleosides and methods for
 treating hepatitis C virus
 INVENTOR(S): Sommadossi, Jean-Pierre; Lacolla, Paulo
 PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Universita
 degli Studi di Cagliari
 SOURCE: PCT Int. Appl., 296 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090121	A2	20011129	WO 2001-US16671	20010523
WO 2001090121	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001074906	A5	20011203	AU 2001-74906	20010523
US 2003050229	A1	20030313	US 2001-864078	20010523
EP 1292603	A2	20030319	EP 2001-941564	20010523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011127	A	20030624	BR 2001-11127	20010523
NO 2002005627	A	20030106	NO 2002-5627	20021122
PRIORITY APPLN. INFO.:			US 2000-206585P	P 20000523
			WO 2001-US16671	W 20010523

OTHER SOURCE(S): MARPAT 136:6296

L15 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AB . . . an inhibiting concn.50 = 15 .mu.g/mL. None of the compds. showed antiviral activity against herpes simplex type 1 or 2 virus at 100 .mu.g/mL.

IT 20724-73-6P 115494-60-5P 116918-69-5P 116918-70-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn., neoplasm inhibiting and virucidal activity of)

ACCESSION NUMBER: 1988:570788 CAPLUS

DOCUMENT NUMBER: 109:170788

TITLE: Nucleosides and nucleotides. LXXXI. Alkyl addition reaction of pyrimidine 2'-ketonucleosides: synthesis of 2'-branched-chain sugar pyrimidine nucleosides

AUTHOR(S): Matsuda, Akira; Itoh, Hiroko; Takenuki, Kenji; Sasaki, Takuma; Ueda, Tohru

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, 060, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1988), 36(3), 945-53

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:170788

=> d 18

L8 HAS NO ANSWERS

L8 STR



Structure attributes must be viewed using STN Express query preparation.